<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00541008</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000569863</org_study_id>
    <secondary_id>FRE-FNCLCC-GEP-03-0603</secondary_id>
    <secondary_id>EU-20761</secondary_id>
    <secondary_id>EUDRACT-2006-003339-62</secondary_id>
    <secondary_id>PFIZER-FRE-FNCLCC-GEP-03-0603</secondary_id>
    <nct_id>NCT00541008</nct_id>
  </id_info>
  <brief_title>Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer</brief_title>
  <official_title>Phase II of Sunitinib (SUTENT®) in First Line for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma - SUPAP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Sunitinib may stop the growth of cancer cells by blocking some of the enzymes
      needed for cell growth and by blocking blood flow to the tumor.

      PURPOSE: This phase II trial is studying how well sunitinib works as first-line therapy in
      treating patients with locally advanced or metastatic papillary renal cell (kidney) cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the objective tumor response rate in patients with locally advanced or
           metastatic papillary renal cell carcinoma treated with sunitinib malate.

      Secondary

        -  To evaluate the safety of this drug in these patients.

        -  To determine time-to-event variables of overall survival, time to disease progression,
           time to response, and duration of response in patients treated with this drug.

      OUTLINE: This is a multicenter study.

      Patients receive oral sunitinib malate once a day on days 1-28. Treatment repeats every 6
      weeks in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed at 28 days and then periodically
      thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2007</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective tumor response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

        Inclusion criteria:

          -  Diagnosis of papillary renal cell carcinoma

               -  Locally advanced or metastatic disease

               -  Type I or type II disease

          -  Progressive disease

          -  Measurable disease defined by RECIST criteria as at least 1 lesion at least 2 cm in
             length by conventional CT scan techniques or at least 1 cm by spiral CT scan

          -  No brain metastases including treated and nonprogressive metastases

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  ECOG performance status 0-1

          -  Life expectancy ≥ 3 months

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 8 g/dL

          -  Total bilirubin ≤ 3 mg/dL

          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases
             are present)

          -  Serum creatinine &lt; 1.5 times ULN

          -  INR ≤ 1.7 or PT ≤ 6 seconds over ULN

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  Patients must be affiliated to a Social Security System

          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests, and other study procedures

        Exclusion criteria:

          -  NCI CTC grade 3 hemorrhage within 4 weeks prior to start of study treatment

          -  Diagnosis of any second malignancy within the past 3 years except for basal cell
             carcinoma, squamous cell skin cancer, or in situ carcinoma of the cervix that has been
             adequately treated with no evidence of recurrent disease within the past 12 months

          -  Spinal cord compression, carcinomatous meningitis, or leptomeningeal disease

          -  Any of the following within the past 12 months prior to study drug administration:

               -  Severe/unstable angina

               -  Myocardial infarction

               -  Coronary artery bypass graft

               -  Symptomatic congestive heart failure

               -  Cerebrovascular accident including transient ischemic attack

               -  Pulmonary embolism

          -  Any of the following conditions:

               -  Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2

               -  Atrial fibrillation of any grade

               -  Prolongation of the QTc interval to &gt; 450 msec for males or &gt; 470 msec for
                  females

          -  Hypertension that cannot be controlled by medications

          -  Inability to swallow oral medications or presence of active inflammatory bowel
             disease, partial or complete bowel obstruction, or chronic diarrhea

          -  Known HIV or AIDS infection

          -  Other severe acute or chronic medical or psychiatric condition, or laboratory
             abnormality that may increase the risk associated with study participation or study
             drug administration

          -  Psychological, familial, sociological, or geographical condition potentially hampering
             compliance with the study protocol and the follow-up schedule

          -  Patients deprived of liberty or placed under the authority of a tutor

        PRIOR CONCURRENT THERAPY:

          -  Recovered from all toxic effects of any prior local treatment to CTCAE version 3.0
             grade ≤ 1

          -  At least 4 weeks since prior radiotherapy

               -  At least 1 week since prior radiotherapy to &lt; 10% of the whole body allowed
                  provided side effects are &lt; grade 2 and there is at least one site for evaluation

          -  More than 2 weeks since prior and no concurrent anticoagulant agents or therapeutic
             doses of warfarin

               -  Low-dose warfarin (up to 2 mg/day) for deep vein thrombosis prophylaxis allowed

               -  Low molecular weight heparin allowed

          -  No prior specific medical systemic therapy (i.e., first-line therapy)

          -  No prior sunitinib malate

          -  No prior investigational agents

          -  No concurrent treatment on another therapeutic clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Ravaud, MD, PhD</last_name>
    <affiliation>Hopital Saint Andre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49036</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Abadie-Lacourtoisie, MD</last_name>
      <phone>33-2-4135-2734</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Stein, MD</last_name>
      <phone>33-3-8166-8240</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Ravaud, MD, PhD</last_name>
      <phone>33-5-5679-5808</phone>
      <email>alain.ravaud@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>C.H.U. de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Malhaire, MD</last_name>
      <phone>33-2-9822-3395</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Sevin, MD</last_name>
      <phone>33-2-3145-5017</phone>
      <email>e.sevin@baclesse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Hopital de la Tronche</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthieu Laramas, MD</last_name>
      <phone>33-4-7676-5333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Departemental</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85025</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck Priou, MD</last_name>
      <phone>33-2-5144-6173</phone>
      <email>frank.priou@chd-vendee.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armelle Caty, MD</last_name>
      <phone>33-3-2029-5942</phone>
      <email>acaty@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Negrier, MD</last_name>
      <phone>33-4-7878-2751</phone>
      <email>negrier@lyon.fnclcc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwenaelle Gravis, MD</last_name>
      <phone>33-4-9122-3740</phone>
      <email>gravisg@marseille.fnclcc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjorie Baciuchka-Palmaro</last_name>
      <phone>33-91-385-708</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Notre-Dame de Bon Secours</name>
      <address>
        <city>Metz</city>
        <zip>57038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Walter, MD</last_name>
      <phone>33-387-553-554</phone>
      <email>s.walter@chr-metz-thionville.rss.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephane Culine, MD</last_name>
      <phone>33-4-6761-8555</phone>
      <email>stculine@valdorel.fnclcc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CRLCC Nantes - Atlantique</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Rolland, MD</last_name>
      <phone>33-2-40-67-99-76</phone>
      <email>F-rolland@nantes.fnclcc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Marc Ferrero, MD</last_name>
      <phone>33-4-9203-1511</phone>
      <email>jean-marc.ferrerero@nice.fnclcc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephane Oudard, MD, PhD</last_name>
      <phone>33-1-5609-3434</phone>
      <email>stephane.oudard@hop.egp.ap-hop-paris.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Michel</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gael Deplanque, MD, MSC, PhD</last_name>
      <phone>33-1-4412-3078</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herve Cure, MD, PhD</last_name>
      <phone>33-3-2650-4382</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Theodore, MD</last_name>
      <phone>33-1-4625-2149</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Chevreau-Dalbianco, MD</last_name>
      <phone>33-5-6142-4118</phone>
      <email>chevreau.christine@claudiusregaud.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Bretonneau de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude Linassier, MD, PhD</last_name>
      <phone>33-2-4747-3827</phone>
      <email>linassier@med.univ-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Escudier, MD</last_name>
      <phone>33-1-4211-5410</phone>
      <email>escudier@igr.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2007</study_first_submitted>
  <study_first_submitted_qc>October 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <last_update_submitted>August 13, 2011</last_update_submitted>
  <last_update_submitted_qc>August 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2011</last_update_posted>
  <keyword>type 1 papillary renal cell carcinoma</keyword>
  <keyword>type 2 papillary renal cell carcinoma</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>stage III renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

